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Kidney and hypertension. There is a unique relationship be- the ultimate determinant of BP must be renal handling
tween the kidney and blood pressure (BP): on the one hand, of sodium according to this concept. This does not imply
renal dysfunction and particularly renal disease cause an in- that hypertension (HT) is a renal disease, but indicatescrease in BP, while on the other hand, high BP accelerates loss
that a renal functional abnormality, i.e. disturbed BP/of function of the diseased kidney. Transplantation studies,
natriuresis relationship, is a sine-qua-non condition forboth in experimental animals and humans, documented that
“blood pressure goes with the kidney,” a normotensive recipi- the development of any type of HT.
ent of a kidney genetically programmed for hypertension (HT) Early studies of Bianchi et al [2] and more definite
will develop HT, while conversely hypertensive patients with
well controlled experimental studies of Rettig et al [3, 4]renal failure receiving the kidney of a normotensive donor
showed that “blood pressure goes with the kidney.”may develop normotension. Family studies showed higher BP
values and more frequent HT in first degree relatives of patients Transplantation of the kidney from a genetically hyper-
with primary glomerulonephritis or diabetic nephropathy, both tension-prone donor rat, even when it had been kept
type 1 and type 2. The notion that HT accelerates the loss of normotensive from weaning by antihypertensive medica-renal function has been proposed at the turn of the century,
tion, caused progressive increase of BP in a recipientbut definite evidence by observational and interventional stud-
animal which was immunologically manipulated to pre-ies has only been provided in the last two decades. The issue has
been much confounded by the mistaken believe that damaged vent a rejection reaction. In contrast, and quantitatively
kidneys require higher BP values in order to function properly. less impressive, transplantation of a kidney graft from a
The mechanisms of BP increase in renal disease comprise:
donor genetically programmed for normotension pro-salt retention, inappropriate activity of the renin-angiotensin
voked normotension in the recipient.system (RAS) and of the sympathetic nerve system as well
as impaired endothelial cell-mediated vasodilatation. There is There is also some analogous evidence in humans. Re-
ample evidence both in primary renal disease (AIPRI and cipients of grafts of genetically hypertension-prone do-
REIN trials) and in nephropathy of type 1 and type 2 di- nors required more antihypertensive medication [5] andabetes (IDNT, RENAAL) that pharmacological blockade of
recipients of kidneys from donors dying from cerebralthe RAS by angiotensin-converting enzyme inhibitors or angio-
hemorrhage, presumably because of hypertension, hadtensin II type 1 receptor blockers has BP-independent renopro-
tective effects. More recently, it has also been shown that a higher risk to develop hypertension [6]. Conversely,
blockade of the sympathetic nerve system has BP-independent patients who had become dialysis-dependent because of
effects on albuminuria and on glomerulosclerosis.
hypertension-induced renal injury turned normotensive
after the kidney of a normotensive donor had been suc-
cessfully grafted [7].
ROLE OF THE KIDNEY IN THE GENESIS RELATION BETWEEN RENAL DISEASE AND
OF HYPERTENSION BLOOD PRESSURE
Guyton [1] proposed the hypothesis, supported by ex- A classical concept had been that renal disease causes
perimental evidence, that the disturbance of the blood
hypertension. Individuals with renal disease develop hy-
pressure (BP)/natriuresis relationship (“renal function
pertension, as had indirectly been concluded very ele-
curve”) is responsible for the BP elevation when renal
gantly by Richard Bright [8]. As early as 1923 Franzfunction is impaired. Because the gain of the BP-natri-
Volhard postulated: “I doubt very much whether hyper-uresis relationship overrides all other regulatory systems,
tension has any useful purpose. We are confronted with
a vicious circle which is responsible for progression of
hypertensive renal disease and the final outcome of renalKey words: hypertension, kidney, renal disease, sodium retention, re-
nin angiotensin system, sympathetic nerve system. insufficiency” [9].
It has recently emerged that the relation is more com- 2002 by the International Society of Nephrology
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Table 2. Blood pressure and urinary albumin excretion in offspringTable 1. Blood pressure status of parents with biopsy-confirmed
glomerulonephritis and controls (after [10]) of parents with type 2 diabetes according to absence or presence
of diabetic nephropathy in the parents (after [12])
Glomerulonephritis Control
(N39) (N87) Parents type 2 diabetes
Without WithHypertensive 36 (57%) 45 (33%)
15/28 fathers 17/54 fathers nephropathy nephropathy
Offspring (N30) Offspring (N26)21/35 mothers 28/84 mothers
Borderline hypertensive 7 (11%) 11 (8%)
Ambulatory blood pressure6/28 fathers 2/54 fathers
mm Hg systolic 11712.9 12516.91/35 mothers 9/84 mothers
Albumin excretion rateNormotensive 20 (32%) 82 (59%)
lg · mL1 4.8 (0.36–17.5) 7.8 (1.04–19.0)7/28 fathers 35/54 fathers
Increase in urinary albumin13/35 mothers 47/84 mothers
after ergonometry 6.3-fold (1.5–231) 16-fold (1.2–236)
Significant difference (by 2 test) between hypertensives versus others with
glomerulonephritis and controls. Definitions are: hypertensive, blood pressure
160/95 mm Hg or on antihypertensive medication; borderline hypertensive,
blood pressure 140–159/90–94 mm Hg; normotensive, blood pressure 140/90
sion, renal failure may develop, although this presumablymm Hg.
is a slow process requiring decades to develop. Perera
[17] noted that during long-term follow-up, renal failure
developed in 92 of 500 patients with essential hyperten-
plex. While undoubtedly renal disease causes hyperten- sion. More recently, Klag et al [18] and Perry et al [19]
sion, there is increasing evidence that a genetic predispo- showed a relation between baseline BP and ESRD in
sition to hypertension increases the risk to develop renal patients without a priori evidence of renal disease. The
disease. This has been shown in patients with glomerulo- evidence that such progressive slow renal damage is pre-
nephritis (Table 1) [10]. Blood pressure values were ventable with antihypertensive agents is not perfectly
higher in the parents of patients with glomerulonephritis convincing [20]. It may be argued, however, that in these
than in the parents of matched controls. The same is studies target blood pressure had not been sufficiently
true for diabetic nephropathy. Higher blood pressure low [21].
values were found in parents of type 1 diabetic patients
as compared to parents of patients without diabetic ne-
RELATIONSHIP OF BLOOD PRESSURE ANDphropathy [11]. In offspring of type 2 diabetic patients
PROGRESSION OF RENAL FAILUREwith as compared to offspring of type 2 diabetic parents
without diabetic nephropathy, Strojek et al [12] found Despite the above postulate of Volhard [8] it took dec-
higher blood pressure values by ambulatory blood pres- ades until the deleterious effect of high BP values on
sure measurement (Table 2). In the offspring of diabetic progression could be proven first by observational stud-
parents with nephropathy, blood pressure was also so- ies in diabetic [22, 23] and later non-diabetic renal disease
dium-dependent compared with offspring of diabetic [24]. In patients with non-diabetic renal disease even
parents without hypertension. more time was required before definite evidence was
Another misconception had been that in order for provided by interventional trials that lowering of blood
BP to rise, an impairment of glomerular filtration rate pressure effectively attenuated the rate of progression
(GFR) was necessary. This is definitely not the case. In in patients with proteinuria exceeding 1 g/day [25].
children with a nephrotic syndrome, Ku¨ster et al [13]
found that blood pressure values, although remaining
WHAT IS THE APPROPRIATE TARGETwithin the range of normotension, were systematically
BLOOD PRESSURE?higher during the nephrotic episode than after remission
There is good evidence that there is a continuous in-of the disease. That a reduction of total kidney GFR is
crease of renal risk with increasing blood pressure with-not a pre-condition for the increase in BP was also shown
out a definite threshold. One piece of observation comesby Stefanski et al (Table 3) [14]. In patients with biopsy-
from the study of Opelz et al [26] that in renal graftconfirmed IgA glomerulonephritis and normal inulin
recipients (as one model of renal damage) 6 year graftclearance, he observed higher 24 h BP values, and this
survival is progressively worse with increasing levels ofwas accompanied by greater septal thickness and evi-
systolic blood pressure (Fig. 1). This concept has recentlydence of impaired compliance of the left ventricle.
been confirmed by a meta-analysis of controlled inter-In the distant past it was well known that hypertension
vention trials in patients with non-diabetic renal diseasemay cause renal failure in the absence of primary renal
where the best renal prognosis was found in individualsdisease. The most frequent cause for this was malignant
with systolic BP 110 mm Hg (abstract: Jafar TH J Amhypertension, i.e. a phase of accelerated hypertension
Soc Nephrol 11:63A, 2000).with arteriolar necrosis [15, 16]. There is also evidence,
however, that even in the absence of malignant hyperten- It is likely, but currently not definitely proven that
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Table 3. Blood pressure status in patients with IgA glomerulonephritis and normal inulin clearence (after [14])
Casual BP mm Hg 24-hour BP Day-time BP Night-time BP
Systolic Diastolic Systolic Diastolic Systolic Diastolic Systolic Diastolic
Glomerulonephritis 125 80 124.5 76.5 129 82 111 64.8
(N20) (110–140) (70–90) (107–135) (69–84) (107–141) (73–88) (97–129) (56.5–72)
Matched controls 120 72.5 114.5 70.5 119 75 103 58
(N20) (105–130) (60–85) (106–135) (62–79) (108–144) (66–87) (91–117) (48–70)
P 0.04 0.04 0.007 0.0006 0.012 0.003 0.003 0.001
Fig. 1. Association of systolic blood pressure
at 1 year after transplantation with subsequent
graft survival in recipients of cadaver kidney
transplants. Data taken from Opelz et al [26],
reprinted with permission.
Fig. 3. Relationship between irbesartan dose and peak renal blood flow
(RBF) response in healthy subjects and patients with type 2 diabetes
mellitus. Despite the fact that type 2 diabetic patients with nephropathy
Fig. 2. Rate of glomerular filtration rate (GFR) decline, dependent on is a low-renin state and that the plasma renin activity (PRA) was lower,
blood pressure and proteinuria. Symbols are: (dashed line) proteinuria the renal vascular response to irbesartan was significantly higher in
1 g/day; (solid line) 1 g/day. Data are taken from Peterson et al diabetic patients (P  0.01). Symbols are: () diabetics; () normals.
[25], reprinted with permission. Data are taken from Price et al [38], reprinted with permission.
ambulatory blood pressure (ABPM) is more predictive with attenuated night-time decrease of BP (non-dippers)
than office BP, particularly an attenuation of the night- had a greater rate of loss of endogenous creatinine clear-
time decrease of BP [27]. In patients with IgA glomerulo- ance than dippers. In type 2 diabetic patients, Nakano
nephritis [28], as well as in patients with more advanced et al found that patients with an obliterated night-time
decrease of BP had a 20-fold higher rate of death (unad-diabetic [29] and non-diabetic renal disease [30], patients
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Table 4. Selected studies showing renoprotection properties of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor
type 1 antagonists (AT-1-RB)
Study [Reference] AIPRI [41] REIN [42] Lewis et al [43] IDNT [44] RENAAL [45]
Various Non-diabetic Nephropathy Nephropathy Nephropathy
Study group nephropathiesa nephropathy type 1 diabetes type 2 diabetes type 2 diabetes
Sample size 583 323 409 1715 1513
Planned duration of follow-up years 3.0 2.2 3.0 2.6 4.5
Study medication (ACEI or AT-1-RB) Benazepril Ramipril Captopril Irbesartan Losartan
Dosage of study medication mg/day 10 1.25–5.0 75 75–300 50–100
Baseline serum creatinine concentration
lmol/L 186 194 115 148 168
Relative risk (95% CI) of ESRD in the 0.89 0.51 0.50 0.83 0.75
treated group (0.06–14.2) (0.30–0.87) (0.18–0.70)b (0.62–1.11)
Relative risk (95% CI) of doubling serum 0.44 0.47 0.48 0.71 0.72
creatinine in the treated group (0.27–0.70) (0.29–0.77) (0.16–0.69) (0.54–0.92)
a Mainly non-diabetic nephropathy; diabetic nephropathy was a cause of renal insufficiency only in 21 of 583 patients
b Combined end points (death, dialysis or kidney transplantation) relative risk
justed for variables) [31] and also a 9-time higher risk tion, Wagner et al [40] found that the expression of
angiotensin II type 1-receptor mRNA in biopsies of pa-to end up on dialysis [32].
tients with glomerulonephritis or diabetic nephropathyFigure 2 shows the post hoc analysis of the MDRD trial
was low, consistent with the notion of homeostatic downby Peterson et al [25]. It shows that in patients with pro-
regulation of the receptor in response to high intrarenalteinuric renal disease with progressively lower achieved
angiotensin II concentrations.mean arterial pressure (MAP) values, the rate of loss of
Today there is no more doubt that pharmacologicalGFR was progressively lower. A minimum rate of loss of
blockade of the RAS by administration of angiotensin-GFR was seen when a MAP of 85–90 mm Hg was reached.
converting enzyme inhibitors (ACEI) or angiotensin IIToday there is widespread consensus that in patients
receptor type 1 blockers (AT-1-RB) provides blood pres-with proteinuric renal disease, blood pressure should be
sure-independent renoprotection. The major studies, i.e.,lowered to values below the currently accepted upper
AIPRI [41] and REIN [42], Lewis et al trial in type 1value of normotension, i.e., 130/85 mm Hg [33, 34]. Most
[43] and IDNT [44] and RENAAL [45], respectively, inauthorities propose a target blood pressure of 120/75
type 2 diabetes are summarized in Table 4.mm Hg [34, 35].
What is currently uncertain is whether ACEI or AT-1-
RB should be titrated according to blood pressure or
DOES SELECTION OF ANTIHYPERTENSIVE whether, despite no further lowering of blood pressure,
AGENTS MATTER? the dose should be increased to optimize the decrease
There is overwhelming evidence for a role of angioten- in proteinuria. According to recent concepts, proteinuria
sin II in progression, both by hemodynamic and by non- is a “nephrotoxin” [46] and exposure of tubular epithelial
hemodynamic factors [36]. It is of interest, however, that cells to protein induces an activated inflammatory phe-
pharmacological blockade of the renin-angiotensin sys- notype [47]. In line with the idea that a further increase
tem (RAS) is renoprotective even in states where pre- in the dose of ACEI or AT-1-RB is sensible was provided
sumably the RAS is suppressed, as indicated by circulat- by the experimental study of Peters et al [48]. It is plausi-
ing plasma renin activity. This paradox can be explained ble that the same principle applies to humans according
by recent observations that within the kidney, the RAS to some preliminary experience [49, 50, 51]. In patients
is activated not only in the juxtaglomerular apparatus, with IgA glomerulonephritis, Palla et al [51] showed that
but also in tubular epithelial cells [37]. This has been increasing doses of lisinopril (5, 10, 15, 20 mg/day) caused
shown in the ablation model, but is also true in diabetes progressive decrease in proteinuria (39, 44, 61, and 67%,
and in ageing. Price et al [38] showed that the increment respectively), although blood pressure was lowered max-
in renal plasma flow upon administration of an angioten- imally (mean 22%) by the lowest dose of lisinopril.
sin receptor blocker, i.e., an index of the angiotensin II- Recently, a role of sympathetic nervous system in pro-
dependency of renal vascular tone, was higher in type 2 gression of renal diseases has been postulated as well.
diabetic patients despite low plasma renin activity (Fig. 3). In experimental animals [52, 53] as well in humans with
It has recently been shown that such suprasensitivity to renal diseases [54], increased efferent sympathetic nerve
angiotensin II type 1-receptor blockade was present only traffic have been shown. There is both experimental and
under conditions of the hyperglycemic clamp, not under clinical evidence that sympathetic overactivity contrib-
utes to progression independently of any effect on bloodconditions of euglycemia [39]. In line with this observa-
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type II diabetes: Evidence for hereditary factors? Kidney Intpressure. Non-hypotensive doses of the central sympath-
51:1602–1607, 1997
icoplegic agent moxonidine reduced the development of 13. Ku¨ster S, Mehls O, Seidel C, Ritz E: Blood pressure in minimal
glomerulosclosis and of albuminuria in subtotally ne- change and other types of nephrotic syndrome. Am J Nephrol 10
(Suppl 1):76–80, 1990phrectomized rats [55]. That this effect is not unique to
14. Stefanski A, Schmidt KG, Waldherr R, Ritz E: Early increase inthe centrally acting drug moxonidine is shown by fur- blood pressure and diastolic left ventricular malfunction in patients
ther experiments: metoprolol at doses which failed to with glomerulonephritis. Kidney Int 50:1321–1326, 1996
15. Kincaid-Smith P, McMicheal J, Murphy EA: The clinical courseaffect systemic blood pressure [56], or surgical denerva-
and pathology of hypertension with papilloedema (malignant hy-tion of the kidney (abstract; Odoni G, J Am Soc Nephrol pertension). Q J Med 27:117–153, 1958
11:626A, 2000) had a similar renoprotective effect. The 16. Byrom FB: The evolution of acute hypertensive arterial disease.
Prog Cardiovasc Dis 17:31–37, 1974in vivo relevance of these observations in humans is
17. Perera GA: Hypertensive vascular disease description and naturaldocumented by the observation of Strojek et al, who history. J Chron Dis 1:33–42, 1955
showed that moxonidine at doses that did not affect 18. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and
end-stage renal disease in men. N Engl J Med 334:13–18, 1996blood pressure caused significant lowering of albumin
19. Perry HM, Miller JP, Fornoff JR, et al: Early predictor of 15-excretion in the morning urine in normotensive, non-
year end-stage renal disease in hypertensive patients. Hypertens
smoking microalbuminuric type I diabetic patients [57]. 25:587–594, 1995
20. Rostand SG, Brown G, Kirk KA, et al: Renal insufficiency inIt emerges from the above that many details concern-
treated essential hypertension. N Engl J Med 320:684–688, 1994ing blood pressure in the kidney are currently unre-
21. Jacobson HR, Striker GE: Report on a workshop to develop
solved. It is also certain, however, that antihypertensive management recommendations for the prevention of progression
in chronic renal disease. Am J Kidney 25:103–106, 1995treatment has become the most effective therapeutic in-
22. Mogensen CE: Long-term antihypertensive treatment inhibitingtervention available today to retard progressive loss of
progression of diabetic nephropathy. BMJ 285:685–688, 1982
renal function. 23. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early
aggressive antihypertensive treatment reduces rate of decline in
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